Sunovion Pharmaceuticals Inc. (Sunovion) announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).
While Sunovion considers dasotraline to be a promising, novel treatment for BED and ADHD, the company believes that further clinical studies would be needed to support a regulatory approval for dasotraline in these indications. Sunovion consistently evaluates and prioritizes its pipeline of potential medicines. At this time, the Company has decided not to pursue any further development of dasotraline.
Headquartered in Marlborough, Massachusetts, Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion invests in ongoing research and development to support individuals with psychiatric, neurological, and respiratory conditions.
This was reported by Sunovion Pharmaceuticals Inc. on May 13, 2020.
Contact information: Kristina Coppola, Director, Portfolio and Corporate Communications, Sunovion Pharmaceuticals Inc., 84 Waterford Drive
Marlborough, Massachusetts 01752; 508-787-4368; Email: email@example.com; Website: www.sunovion.us